A new class of dual-targeted antivirals: Monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2

Journal of Infectious Diseases

Volumn 201, Issue 4, 2010, Pages 635-643

  Vanpouille, Christophe ^a   Lisco, Andrea ^a   Derudas, Marco ^c   Saba, Elisa ^a   Grivel, Jean Charles ^a   Brichacek, Beda ^a   Scrimieri, Francesca ^a   Schinazi, Raymond ^b   Schols, Dominique ^d   McGuigan, Christopher ^c   Balzarini, Jan ^d   Margolis, Leonid ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR DERIVATIVE; ANTIVIRUS AGENT; CF 2648; CF 2649; CF 2676; CF 2681; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONTROL GROUP; CONTROLLED STUDY; DRUG STRUCTURE; EX VIVO STUDY; FLOW CYTOMETRY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS TRANSMISSION;

ACYCLOVIR; ANTIVIRAL AGENTS; CELL LINE; CERVIX UTERI; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HISTOCYTOCHEMISTRY; HIV INFECTIONS; HIV-1; HUMANS; PALATINE TONSIL; PRODRUGS; T-LYMPHOCYTES; VIRUS REPLICATION;

EID: 75749153257     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/650343     Document Type: Article

References (46)

1. Cohen MS. HIV and sexually transmitted diseases: lethal synergy. Top HIV Med 2004; 12:104-107.
2. Corey L. Synergistic copathogens - HIV-1 and HSV-2. N Engl J Med 2007; 356:854-856.
3. Wenner M. Virology: the battle within. Nature 2008; 451:388-389.
4. Lisco A, Vanpouille C, Margolis L. Coinfecting viruses as determinants of HIV disease. Curr HIV/AIDS Rep 2009; 6:5-12.
5. Van de Perre P, Segondy M, Foulongne V, et al. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis 2008; 8:490-497. (Pubitemid 352005823)
6. Delany-Moretlwe S, Lingappa JR, Celum C. New insights on interactions between HIV-1 and HSV-2. Curr Infect Dis Rep 2009; 11:135-142.
7. Abu-Raddad LJ, Magaret AS, Celum C, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One 2008; 3:e2230.
8. Sobngwi-Tambekou J, Taljaard D, Lissouba P, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis 2009; 199:958-964.
9. Elion GB. The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother 1983; 12(suppl B):9-17.
10. Lisco A, Vanpouille C, Tchesnokov EP, et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 2008; 4:260-270.
11. Grivel JC, Margolis L. Use of human tissue expiants to study human infectious agents. Nat Protoč 2009; 4:256-269.
12. Derudas M, Carta D, Brancale A, et al. The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. J Med Chem 2009; 52:5520-5530.
13. Grivel JC, Elliott J, Lisco A, et al. HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1. AIDS 2007; 21:1263-1272. (Pubitemid 46883480)
14. Snoeck R, Andrei G, De Clercq E. Chemotherapy of varicella zoster virus infections. Int J Antimicrob Agents 1994; 4:211-226. (Pubitemid 24235256)
15. Cahard D, McGuigan C, Balzarini J. Aryloxy phosphoramidate triesters as pro-tides. Mini Rev Med Chem 2004; 4:371-381.
16. Glushakova S, Baibakov B, Margolis LB, Zimmerberg J. Infection of human tonsil histocultures: a model for HIV pathogenesis. Nat Med 1995; 1:1320-1322.
17. Fletcher PS, Elliott J, Grivel JC, et al. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 2006; 20:1237-1245. (Pubitemid 44030371)
18. Karlsson I, Grivel JC, Chen SS, et al. Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue. J Virol 2005; 79:11151-11160. (Pubitemid 41170656)
19. McGuigan C, Harris SA, Daluge SM, et al. Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency. J Med Chem 2005; 48:3504-3515. (Pubitemid 40664102)
20. McGuigan C, Hassan-Abdallah A, Srinivasan S, et al. Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives. J Med Chem 2006; 49:7215-7226. (Pubitemid 44886007)
21. Balzarini J, Karlsson A, Aquaro S, et al. Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Proc Natl Acad Sci U S A 1996; 93:7295-7299. (Pubitemid 26243543)
22. McGuigan C, Cahard D, Sheeka HM, De Clercq E, Balzarini J. Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. J Med Chem 1996; 39:1748-1753. (Pubitemid 26124246)
23. Perrone P, Luoni GM, Kelleher MR, et al. Application of the phosphoramidate ProTide approach to 4'-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside. J Med Chem 2007; 50:1840-1849. (Pubitemid 46626594)
24. Lackey DB, Groziak MP, Sergeeva M, et al. Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. Biochem Pharmacol 2001; 61:179-189. (Pubitemid 32121782)
25. McGuigan C, Thiery JC, Daverio F, Jiang WG, Davies G, Mason M. Anti-cancer ProTides: tuning the activity of BVDU phosphoramidates related to thymectacin. Bioorg Med Chem 2005; 13:3219-3227.
26. Hu Q, Frank I, Williams V, et al. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 2004; 199:1065-1075. (Pubitemid 38619903)
27. Daxecker H, Raab M, Cichna M, Markl P, Muller MM. Determination of the effects of mycophenolic acid on the nucleotide pool of human peripheral blood mononuclear cells in vitro by high-performance liquid chromatography. Clin Chim Acta 2001; 310:81-87. (Pubitemid 32727320)
28. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1:417-422.
29. Malkevich N, Womack C, Pandya P, Grivel JC, Fauci AS, Margolis L. Human immunodeficiency virus type 1 (HIV-1) non-B subtypes are similar to HIV-1 subtype B in that coreceptor specificity is a determinant of cytopathicity in human lymphoid tissue infected ex vivo. J Virol 2001; 75:10520-10522. (Pubitemid 32948086)
30. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185:45-52. (Pubitemid 34043015)
31. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83.
32. MoleL,RipichS,MargolisD,HolodniyM. Theimpactofactiveherpessimplexvirusinfectiononhumanimmunodeficiencyvirusload. JInfectDis1997;176:766-770.(Pubitemid27360547)
33. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998; 280:61-66. (Pubitemid 28414998)
34. Posavad CM, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV- 1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004; 190:693-696. (Pubitemid 39049997)
35. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560-1571.
36. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-2119. (Pubitemid 351902179)
37. Hudson CP. Effect of aciclovir on HIV-1 acquisition in HSV-2-positive patients. Lancet 2008; 372:1298.
38. Lisco A, Vanpouille C. HSV-2 suppression and the incidence of HIV N Engl J Med 2008; 359:535.
39. Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8:553-563.
40. Stirratt MJ, Gordon CM. Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep 2008; 5:186-192.
41. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356:790-799. (Pubitemid 46294611)
42. Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008; 198:1804-1808.
43. Dunne EF, Whitehead S, Sternberg M, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008; 49:77-83.
44. Delany S, Miaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009; 23:461-469.
45. Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV- 1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007; 196:1500-1508.
46. Zuckerman RA, Lucchetti A, Whittington WL, et al. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. AIDS 2009; 23:479-483.